… either aspirin plus clopidogrel (DAPT), aspirin plus rivaroxaban … among patients with stable
atherosclerotic vascular disease, … -term prevention of recurrent ischemic events. In particular, …

… b The addition of clopidogrel on top of low-dose aspirin and rivaroxaban can be decided …
aspirin) is advised to avoid cardiovascular events over time. Only in one study with 28 patients, …

… poses a greater risk of bleeding without a difference in major adverse cardiovascular
events when compared to patients that received OAC with only a single antiplatelet agent. …

… as aspirin in preventing one fifth to one third of all important cardiovascular events should …
for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or …

… efficacy of aspirin for the secondary prevention of atherosclerotic cardiovascular disease (…
1 ; however, evidence on aspirin use for primary prevention has been controversial. In 2022, …

… dual antiplatelet therapy in coronary artery disease developed in … PCI, patients in the 1- to
2-month DAPT group were to stop … DAPT with aspirin and clopidogrel. Others might argue that …

… In conclusion, among patients who took ticagrelor (90 mg twice daily), 50 mg … Patients stop
ticagrelor in advance or switch ticagrelor to clopidogrel mainly because of bleeding events […

… In addition, the effectiveness of clopidogrel may be limited by high … stable coronary artery
disease or ACS, 6 the clinical outcomes between ticagrelor alone and ticagrelor plus aspirin in …

… heart disease and other pathologies of the cardiovascular system … Cardiovascular events
such as sudden death, non-fatal MI … of patients receiving combined treatment with clopidogrel + …

… than 12 months that compared aspirin (ASA) monotherapy with … clopidogrel was published
in 2021 (7). An updated analysis of available RCTs on antithrombotic therapy among patients …